LED Dental Partners with London Drugs to Facilitate Oral Cancer Screenings for General Public
LED Dental to Provide VELscopes for London Drugs Oral Cancer Screening Program
"This is the first time we are working with colleagues outside the dental field to find ways to combat the minimally-known, but deadly, oral cancer," said Dr. Samson Ng. Abnormal areas discovered during screening where follow-up is recommended will be documented on a form and provided to the customer to take to their dentist or healthcare provider. This service, initially to be offered at no cost to the customers, will then be offered at either no cost or a very low cost to customers on an on-going basis depending on the results of a survey that London Drugs will conduct among customers.
"We continue to see the pharmacy expanding its role in the health of Canadians," said John Tse, London Drugs vice president. "This is a first ever for a pharmacy in Canada and we appreciate the support of LED Dental to help us build the pilot program."
"We are pleased to be able to provide VELscope® Vx Systems to London Drugs and have the VELscope® Vx play an important role in oral cancer screening for the general public," stated Dr. David Gane, CEO, LED Medical. "Our goal through this program is to assist London Drugs in contributing to a reduced incidence of oral cancer in Canada through early detection."
This screening program will enhance the health of the general public. Access to preventative dental care varies across different income groups, but some estimates suggest the percentage of the population that does not have regular access to a dentist can be as high as 17%. This program also helps to respond to the growing demand for oral cancer screening which has risen recently because of the aging population, a growing awareness of oral cancer and the importance of early detection. Statistics from SEER (the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute) indicate that 65% of oral cancer is discovered in the later stages when the survival rate is only 54%, whereas the 31% of cases that are found in the early stages have an 83% survival rate. Currently, 37% of patients diagnosed with oral cancer die within five years of their diagnosis.
The Company manufactures and markets the VELscope® Vx System, the dental industry´s leading adjunctive screening device for helping health-care providers discover and define the extent of a wide range of oral mucosal abnormalities - from viral, fungal and bacterial infections to cancer and pre-cancer. To-date, more than 25 million VELscope® Vx exams have been performed by more than 12,000 dentists in 23 countries.
About London Drugs
Founded in 1945, B.C.-based London Drugs has 79 stores in more than 35 major markets throughout British Columbia, Alberta, Saskatchewan and Manitoba including its online store www.londondrugs.com London Drugs offers consumers a range of products from digital cameras and cosmetics to computers and televisions. Renowned for its creative approach to retailing, the company employs more than 7,500 people with pharmacy and health care services being the heart of its business. Committed to innovation and superior customer service, London Drugs has established itself as a reputable and caring company and continues to position itself for future growth and development.
About LED Medical Diagnostics Inc.
Founded in 2003 and headquartered in Burnaby, British Columbia, Canada, LED Medical Diagnostics Inc., through its wholly-owned subsidiaries LED Dental Inc. and LED Dental Ltd, provide dentists and oral health specialists with advanced diagnostic imaging products and software, in addition to the award-winning VELscope® Vx tissue fluorescence visualization technology. Backed by an experienced leadership team and dedicated to a higher level of service and support, LED Dental is committed to providing dental practitioners with the best technology available by identifying and adding leading products to its growing portfolio.
The Company is currently listed on the TSX Venture Exchange (TSX-V) under the symbol LMD, the OTCQX under the symbol LEDIF, as well as the Frankfurt Stock Exchange under the symbol LME. For more information, call 844.952.7327 or visit www.leddental.com/investor-relations.
LED Medical Diagnostics
Phone: 604.434.4614 x227
Forward Looking Statement
Forward Looking Statements
This press release contains statements which, to the extent that they are not recitations of historical fact, may constitute forward-looking information under applicable Canadian securities legislation that involve risks and uncertainties. Such forward-looking statements or information include statements regarding, but not limited to the Company's future growth strategy, its distribution strategy and product offerings, potential expansion of the Company's technology to other medical applications or markets, or the potential introduction of new technologies by the Company. Persons reading this press release are cautioned that such statements or information are only predictions, and that the Corporation's actual future results or performance may be materially different. Factors that could cause actual events or results to differ materially from those suggested by these forward-looking statements include, but are not limited to competition risks, distributor risks, product development risks such as regulatory, design, intellectual property and other factors described in the Corporation's reports filed on SEDAR including its Annual Information Form and financial report for the year ended December 31, 2013. These and other factors should be considered carefully and readers should not place undue reliance on such forward-looking information. All forward-looking statements made in this press release are qualified by this cautionary statement and there can be no assurance that actual results or developments anticipated by the Company will be realized. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.